Drugs / 124I-PUH71
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT01269593 | Dec 2010 → Dec 2026 expected | non-Hodgkin lymphoma, plasma cell myeloma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 124I-PUH71 | “A dose of up to 11.0 mCi (range: 4.0-11.0 mCi) of 124I-PUH71 will be administered intravenously with the patient at rest.” NCT01269593 ↗ |
| Known as | PUH71 | “The purpose of this study is to see how a new drug, named PUH71, accumulates in the different parts of the body \& inside tumors and how long PUH71 lasts in the blood, when...” NCT01269593 ↗ |
| Modality | Diagnostic / imaging agent | “whether PUH71 might be used as a drug for detecting tumors with scanner machines” NCT01269593 ↗ |
| Route | Intravenous | “will be administered intravenously with the patient at rest” NCT01269593 ↗ |